Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study

INTRODUCTION: Patients with intermediate or locally advanced hepatocellular carcinoma (HCC) who are not eligible for radical treatment typically have a poor overall prognosis. Treatment strategies that can convert unresectable HCC into resectable HCC may improve patient survival. We conducted a sing...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lijun, Wang, Hongwei, Cui, Yong, Liu, Ming, Jin, Kemin, Xu, Da, Wang, Kun, Xing, Baocai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977802/
https://www.ncbi.nlm.nih.gov/pubmed/36874115
http://dx.doi.org/10.3389/fonc.2023.1115109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977802/
https://www.ncbi.nlm.nih.gov/pubmed/36874115
http://dx.doi.org/10.3389/fonc.2023.1115109

Ejemplares similares